<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668638</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2020-19</org_study_id>
    <nct_id>NCT04668638</nct_id>
  </id_info>
  <brief_title>Impact of Respiratory Rehabilitation on Quality of Life in Patients With Hyperventilation Syndrome</brief_title>
  <acronym>RESPIR-HVS</acronym>
  <official_title>Impact of Respiratory Rehabilitation on Quality of Life, Measures by the SF-36 Score, in Patients With Hyperventilation Syndrome: Crossover, Prospective and Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hyperventilation syndrome is a quite frequent pathology, affecting up to 10% of the&#xD;
      general population and 40% of the asthmatic population. Its physiopathology is still badly&#xD;
      known and even if it is a benign affection, its associated comorbidities and symptomatology&#xD;
      greatly decrease the patients' quality of life. Yet, no medicinal treatments have been proved&#xD;
      useful, but prescribers noticed improvements after physiotherapy. Given that the&#xD;
      physiotherapy impact on hyperventilation syndrome is not well described in the literature,&#xD;
      this study aims to scientifically ascertain physiotherapy benefits on quality of life and&#xD;
      symptomatology in hyperventilation syndrome-suffering patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will be divided into two groups:&#xD;
Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.&#xD;
Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of respiratory rehabilitation on Quality of life</measure>
    <time_frame>Day 0</time_frame>
    <description>Quality of life will be evaluated with the SF-36 score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of respiratory rehabilitation on Quality of life</measure>
    <time_frame>Month 2</time_frame>
    <description>Quality of life will be evaluated with the SF-36 score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of respiratory rehabilitation on Quality of life</measure>
    <time_frame>Month 4</time_frame>
    <description>Quality of life will be evaluated with the SF-36 score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in symptomatology</measure>
    <time_frame>Day 0</time_frame>
    <description>Change in symptomatology will be evaluated on the Nijmegen questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptomatology</measure>
    <time_frame>Month 2</time_frame>
    <description>Change in symptomatology will be evaluated on the Nijmegen questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptomatology</measure>
    <time_frame>Month 4</time_frame>
    <description>Change in symptomatology will be evaluated on the Nijmegen questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hyperventilation Syndrome</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Respiratory rehabilitation</intervention_name>
    <description>Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive hyperventilation syndrome diagnosis&#xD;
&#xD;
          -  Having a social security insurance&#xD;
&#xD;
          -  Being at least 18 years old&#xD;
&#xD;
          -  Having given their written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being put under guardianship or curatorship&#xD;
&#xD;
          -  Having seen a physiotherapist for a respiratory rehabilitation in the last three&#xD;
             months&#xD;
&#xD;
          -  Suffering from a chronic and degenerative pathology (chronic obstructive pulmonary&#xD;
             disease, Parkinson's disease, idiopathic fibrosis, …)&#xD;
&#xD;
          -  Not being able to receive the respiratory rehabilitation from our care providers&#xD;
&#xD;
          -  Already having received a rehabilitation for hyperventilation syndrome&#xD;
&#xD;
          -  Not speaking French or not being unable to complete the questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis-François BIRNESSER</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie POUGOUE TOUKO</last_name>
    <phone>+33238744086</phone>
    <email>elodie.pougoue-touko@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis-François BIRNESSER</last_name>
      <phone>+33238514444</phone>
      <email>louis-francois.birnesser@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Louis-François BIRNESSER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gardner WN. The pathophysiology of hyperventilation disorders. Chest. 1996 Feb;109(2):516-34. Review.</citation>
    <PMID>8620731</PMID>
  </reference>
  <reference>
    <citation>Lewis RA, Howell JB. Definition of the hyperventilation syndrome. Bull Eur Physiopathol Respir. 1986 Mar-Apr;22(2):201-5.</citation>
    <PMID>3708188</PMID>
  </reference>
  <reference>
    <citation>Thomas M, McKinley RK, Freeman E, Foy C. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ. 2001 May 5;322(7294):1098-100.</citation>
    <PMID>11337441</PMID>
  </reference>
  <reference>
    <citation>Lewis T, Cotton, Barcroft J, Dufton D, Milroy TR, Parsons TR. BREATHLESSNESS IN SOLDIERS SUFFERING FROM IRRITABLE HEART. Br Med J. 1916 Oct 14;2(2911):517-9.</citation>
    <PMID>20768329</PMID>
  </reference>
  <reference>
    <citation>van Dixhoorn J, Duivenvoorden HJ. Efficacy of Nijmegen Questionnaire in recognition of the hyperventilation syndrome. J Psychosom Res. 1985;29(2):199-206.</citation>
    <PMID>4009520</PMID>
  </reference>
  <reference>
    <citation>Vansteenkiste J, Rochette F, Demedts M. Diagnostic tests of hyperventilation syndrome. Eur Respir J. 1991 Apr;4(4):393-9.</citation>
    <PMID>1855568</PMID>
  </reference>
  <reference>
    <citation>Nixon PG. Effort syndrome: hyperventilation and reduction of anaerobic threshold. Biofeedback Self Regul. 1994 Jun;19(2):155-69.</citation>
    <PMID>7918753</PMID>
  </reference>
  <reference>
    <citation>Chenivesse C, Similowski T, Bautin N, Fournier C, Robin S, Wallaert B, Perez T. Severely impaired health-related quality of life in chronic hyperventilation patients: exploratory data. Respir Med. 2014 Mar;108(3):517-23. doi: 10.1016/j.rmed.2013.10.024. Epub 2013 Nov 7.</citation>
    <PMID>24269004</PMID>
  </reference>
  <reference>
    <citation>Kraft AR, Hoogduin CA. The hyperventilation syndrome. A pilot study on the effectiveness of treatment. Br J Psychiatry. 1984 Nov;145:538-42.</citation>
    <PMID>6388711</PMID>
  </reference>
  <reference>
    <citation>Van De Ven LL, Mouthaan BJ, Hoes MJ. Treatment of the hyperventilation syndrome with bisoprolol: a placebo-controlled clinical trial. J Psychosom Res. 1995 Nov;39(8):1007-13.</citation>
    <PMID>8926595</PMID>
  </reference>
  <reference>
    <citation>Hoes MJ, Colla P, Folgering H. Clomipramine treatment of hyperventilation syndrome. Pharmakopsychiatr Neuropsychopharmakol. 1980 Jan;13(1):25-8.</citation>
    <PMID>7367465</PMID>
  </reference>
  <reference>
    <citation>Jones M, Harvey A, Marston L, O'Connell NE. Breathing exercises for dysfunctional breathing/hyperventilation syndrome in adults. Cochrane Database Syst Rev. 2013 May 31;(5):CD009041. doi: 10.1002/14651858.CD009041.pub2. Review.</citation>
    <PMID>23728685</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperventilation syndrome</keyword>
  <keyword>Respiratory rehabilitation</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperventilation</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

